NCT04648800View on ClinicalTrials.gov

Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland

PHASE3UnknownINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

July 7, 2020

Primary Completion Date

December 31, 2020

Study Completion Date

April 30, 2021

Conditions
Covid19BCG Vaccination ReactionSARS-CoV Infection
Interventions
DRUG

BCG-10 vaccine

"The BCG-10 anti-tuberculosis vaccine~* powder and solvent for preparing a suspension for intradermal injections of Vaccinum tuberculosis (BCG) cryodesiccatum;~* lyophilised BCG vaccine~* one dose (0.1 ml) contains 50 micrograms of half-dried mass of BCG mycobacteria, which corresponds to 150,000 - 600,000 of live BCG bacilli- the Brazilian Moreau sub-strain."

DRUG

0.9% saline

0.9% saline

Trial Locations (6)

Unknown

RECRUITING

Department of Anesthesiology and Intensive Care, University Clinical Center, School of Medicine in Katowice, Medical University of Silesia, Katowice

RECRUITING

Stefan Żeromski Specialist Hospital, Krakow

RECRUITING

Saint Jadwiga Śląska Hospital, Trzebnica

RECRUITING

Department of Pediatrics, Bielanski Hospital,, Warsaw

RECRUITING

Praski Hospital, Warsaw

35-959

RECRUITING

Voivodeship Hospital nr 2 in the Name of The Saint Queen Jadwiga, University of Rzeszów, Poland, Rzeszów

Sponsors
All Listed Sponsors
collaborator

Medical Research Agency, Poland

OTHER_GOV

lead

Hanna Czajka

OTHER

NCT04648800 - Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland | Biotech Hunter | Biotech Hunter